These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19540337)

  • 1. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
    Masson K; Rönnstrand L
    Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
    Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
    Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
    Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
    Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.
    Usher SG; Radford AD; Villiers EJ; Blackwood L
    Exp Hematol; 2009 Jan; 37(1):65-77. PubMed ID: 18977066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
    Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
    Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic receptor tyrosine kinase in leukemia.
    Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
    Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
    Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
    Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
    Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
    J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FES kinases are required for oncogenic FLT3 signaling.
    Voisset E; Lopez S; Chaix A; Georges C; Hanssens K; Prébet T; Dubreuil P; De Sepulveda P
    Leukemia; 2010 Apr; 24(4):721-8. PubMed ID: 20111072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.